Results 251 to 260 of about 33,791,512 (292)
Some of the next articles are maybe not open access.
The discovery of glucagon-like peptide 1
Regulatory Peptides, 2005The discovery of glucagon-like peptide 1 (GLP-1) began more than two decades ago with the observations that anglerfish islet proglucagon messenger RNAs (mRNAs) contained coding sequences for two glucagon-related peptides arranged in tandem. Subsequent analyses revealed that mammalian proglucagon mRNAs encoded a precursor containing the sequence of ...
openaire +2 more sources
Glucagon-like peptide-1 agonists
BMJ, 2012Cannot be recommended strictly for weight reduction until their benefits and risks are ...
openaire +2 more sources
The Physiology of Glucagon-like Peptide 1
Physiological Reviews, 2007Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the ...
openaire +3 more sources
Glucagon-like peptide-1 and glucagon-like peptide-2
Best Practice & Research Clinical Endocrinology & Metabolism, 2004The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L. Baggio, Daniel J. Drucker
openaire +1 more source
Glucagon-like peptide-1 in the pathogenesis of obesity
Drug News & Perspectives, 1998The recently discovered gut peptide glucagon-like peptide-1 (GLP-1) is one of many peptides implicated in the short-term regulation of appetite. GLP-1 is a 30-amino-acid peptide that is produced in and secreted from the L cells of the intestinal mucosa after intake of a mixed meal.
E, Näslund, P M, Hellström
openaire +2 more sources
Glucagon-like peptide 1 in health and disease
Nature Reviews Endocrinology, 2018In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also delays gastric emptying and increases satiety. In patients with type 2 diabetes mellitus (T2DM), supraphysiological doses of GLP1 normalize the endogenous insulin ...
Andreas Andersen +3 more
openaire +3 more sources
Glucagon-Like Peptide 1—A Cardiologic Dimension
Trends in Cardiovascular Medicine, 2010Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant.
Treiman, Marek +3 more
openaire +3 more sources
Glucagon-like peptide-1 receptor
Current BiologyMichael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire +2 more sources
Glucagon-like Peptide-1 and Islet Lipolysis
Hormone and Metabolic Research, 2004A role for glucagon-like peptide 1 (GLP-1) has been suggested in stimulating beta-cell lipolysis via elevation of cAMP and activation of protein kinase A, which in turn may activate hormone-sensitive lipase (HSL), thereby contributing to fatty acid generation (FFA) from intracellular triglyceride stores.
M, Sörhede Winzell, B, Ahrén
openaire +2 more sources
Glucagon-like peptide-1 medicines and cancer
Nature CancerGlucagon-like peptide-1 (GLP-1) medicines reduce food intake, body weight, insulin resistance and inflammation, thus improving outcomes for people with type 2 diabetes and obesity and potentially contributing to decreased cancer incidence. GLP-1 medicines acting through weight loss-dependent and weight loss-independent mechanisms hold potential for ...
Julian M. Yabut, Daniel J. Drucker
openaire +2 more sources